Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 25;63(5):e02016-18.
doi: 10.1128/AAC.02016-18. Print 2019 May.

Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions

Sauzanne G Khalilieh  1 , Ka Lai Yee  2 , Rosa I Sanchez  2 , Li Fan  2 , Matt S Anderson  2 , Monali Sura  2 , Tine Laethem  2 , Scott Rasmussen  3 , Luc van Bortel  4 , Griet van Lancker  4 , Marian Iwamoto  2
Affiliations

Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions

Sauzanne G Khalilieh et al. Antimicrob Agents Chemother. .

Abstract

Identifying and understanding potential drug-drug interactions (DDIs) are vital for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. This article discusses DDIs between doravirine, a nonnucleoside reverse transcriptase inhibitor (NNRTI), and cytochrome P450 3A (CYP3A) substrates and drugs that modulate CYP3A activity. Consistent with previously published in vitro data and DDI trials with the CYP3A substrates midazolam and atorvastatin, doravirine did not have any meaningful impact on the pharmacokinetics of the CYP3A substrates ethinyl estradiol and levonorgestrel. Coadministration of doravirine with CYP3A inhibitors (ritonavir or ketoconazole) increased doravirine exposure approximately 3-fold. However, these increases were not considered clinically meaningful. Conversely, previously published trials showed that coadministered CYP3A inducers (rifampin and rifabutin) decreased doravirine exposure by 88% and 50%, respectively (K. L. Yee, S. G. Khalilieh, R. I. Sanchez, R. Liu, et al., Clin Drug Investig 37:659-667, 2017 [https://doi.org/10.1007/s40261-017-0513-4]; S. G. Khalilieh, K. L. Yee, R. I. Sanchez, R. Liu, et al., J Clin Pharmacol 58:1044-1052, 2018 [https://doi.org/10.1002/jcph.1103]), while doravirine exposure following prior efavirenz administration led to an initial reduction in doravirine exposure of 62%, but the reduction became less pronounced with time (K. L. Yee, R. I. Sanchez, P. Auger, R. Liu, et al., Antimicrob Agents Chemother 61:e01757-16, 2017 [https://doi.org/10.1128/AAC.01757-16]). Overall, the coadministration of doravirine with CYP3A inhibitors and substrates is, therefore, supported by these data together with efficacy and safety data from clinical trials, while coadministration with strong CYP3A inducers, such as rifampin, cannot be recommended. Concomitant dosing with rifabutin (a CYP3A inducer less potent than rifampin) is acceptable if doravirine dosing is adjusted from once to twice daily; however, the effect of other moderate inducers on doravirine pharmacokinetics is unknown.

Keywords: HIV; doravirine; drug-drug interactions; nonnucleoside reverse transcriptase inhibitor (NNRTI).

PubMed Disclaimer

Figures

FIG 1
FIG 1
Elimination pathways of doravirine in humans.
See this image and copyright information in PMC

References

    1. Kaulich-Bartz J, Dam W, May MT, Lederberger B, Widmer U, Phillips AN, Grabar S, Mocroft A, Vilaro J, van Sighem A, Moreno S, Dabis F, Monforte AD, Teira R, Ingle SM, Sterne JA. 2013. Insurability of HIV-positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies. AIDS 27:1641–1655. doi:10.1097/QAD.0b013e3283601199. - DOI - PMC - PubMed
    1. Trickey A, May MT, Vehreschild JJ, Obel N, Gill MJ, Crane HM, Boesecke C, Patterson S, Grabar S, Cazanave C, Cavassini M, Shepherd L, Monforte AD, van Sighem A, Saag M, Lampe F, Hernando V, Montero M, Zangerle R, Justice AC, Sterling T, Ingle SM, Sterne JAC, Boulle A, Stephan C, Miro JM, Chêne G, Costagliola D, Dabis F, del Amo J, Guest J, Haerry DH-U, Hogg R, Justice A, Smith C, Reiss P, Saag M, Teira R, Williams M, May MT. 2017. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV 4:e349–e356. doi:10.1016/S2352-3018(17)30066-8. - DOI - PMC - PubMed
    1. Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, Bertisch B, Bernasconi E, Weber R. 2011. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 53:1130–1139. doi:10.1093/cid/cir626. - DOI - PubMed
    1. Vance DE, Mugavero M, Willig J, Raper JL, Saag MS. 2011. Aging with HIV: a cross-sectional study of comorbidity prevalence and clinical characteristics across decades of life. J Assoc Nurses AIDS Care 22:17–25. doi:10.1016/j.jana.2010.04.002. - DOI - PubMed
    1. Tseng A, Szadkowski L, Walmsley S, Salit I, Raboud J. 2013. Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients. Ann Pharmacother 47:1429–1439. doi:10.1177/1060028013504075. - DOI - PubMed

Publication types

LinkOut - more resources